NordICC colonoscopy study results should be viewed with caution—longer follow-up needed

KU Cancer Center deploys new mobile cancer screening bus

The University of Kansas Cancer Center and its outreach network, the Masonic Cancer Alliance, announced a new effort to provide cancer screening throughout the cancer center’s catchment area. Known as HOPE on Wheels: Health, Outreach, Prevention, and Education, a 42-foot bus will help ensure that geography isn’t a barrier to detecting cancers earlier.

March 20, 2026

Vol.52 No.11

Podcast

With five-year cancer survival at an all-time high, does this mean people are living longer?

“It's really, really important that every year since 1991, cancer mortality has dropped by a little bit, and it did again!” said Paul Goldberg, editor and publisher of The Cancer Letter. “Now, mortality is a good metric, age-adjusted mortality. As far as survival, well, that's not so good.”

January 21, 2026

Clinical Health Equity

New Medicaid work requirements could lead to 1.6 million missed cancer screenings over two years

New Medicaid work requirements included in President Donald Trump’s “One Big Beautiful Bill Act” could result in as many as 1.6 million missed screenings for breast, colon, and lung cancers within the first two years, researchers at the University of Chicago reported in a paper published in JAMA Oncology earlier this month.

Blood test may help identify which colon cancer patients benefit from NSAIDs

A blood test could help doctors decide which patients with colon cancer should receive anti-inflammatory medication along with chemotherapy after surgery.

January 09, 2026

Vol.52 No.1

Guest Editorial

Mail-out colorectal cancer screening programs extend, rather than replace, clinical care

As a gastroenterologist, I’ve had the sobering experience of delivering a colorectal cancer diagnosis for far too many patients and family members. Some meant to get screened but never found the time. Others thought it didn’t apply to them or assumed it would be too inconvenient.

GLP-1 drugs linked to dramatically lower death rates in colon cancer patients

GLP-1 receptor agonists—the class of drugs behind Ozempic, Wegovy, and Mounjaro—may do more than regulate blood sugar and weight.

November 21, 2025

Vol.51 No.43

NordICC colonoscopy study results should be viewed with caution—longer follow-up needed

YOU MAY BE INTERESTED IN

KU Cancer Center deploys new mobile cancer screening bus

With five-year cancer survival at an all-time high, does this mean people are living longer?

New Medicaid work requirements could lead to 1.6 million missed cancer screenings over two years

Blood test may help identify which colon cancer patients benefit from NSAIDs

Mail-out colorectal cancer screening programs extend, rather than replace, clinical care

GLP-1 drugs linked to dramatically lower death rates in colon cancer patients

Renew today!

Subscriber content

Never miss an issue!

Login

NordICC colonoscopy study results should be viewed with caution­—longer follow-up needed

YOU MAY BE INTERESTED IN

KU Cancer Center deploys new mobile cancer screening bus

With five-year cancer survival at an all-time high, does this mean people are living longer?

New Medicaid work requirements could lead to 1.6 million missed cancer screenings over two years

Blood test may help identify which colon cancer patients benefit from NSAIDs

Mail-out colorectal cancer screening programs extend, rather than replace, clinical care

GLP-1 drugs linked to dramatically lower death rates in colon cancer patients

Never miss an issue!

Login

NordICC colonoscopy study results should be viewed with caution—longer follow-up needed